134 results on '"Boeva V"'
Search Results
2. EP07.02-003 Characterization of the Extracellular Vesicle-Derived Transcriptome in Malignant Pleural Mesothelioma
- Author
-
Kraft, A., primary, Meerang, M., additional, Kirschner, M.B., additional, Boeva, V., additional, and Opitz, I., additional
- Published
- 2022
- Full Text
- View/download PDF
3. A Method for Identification and Ranking of Requirements Sources
- Author
-
Klotins, E., Boeva, V., Wnuk, Krzysztof, Unterkalmsteiner, M., Gorschek, T., Jansen, S., Klotins, E., Boeva, V., Wnuk, Krzysztof, Unterkalmsteiner, M., Gorschek, T., and Jansen, S.
- Abstract
Context: Requirements engineering (RE) literature acknowledges the importance of early stakeholder identification. The sources of requirements are many and also constantly changing as the market and business constantly change. Identifying and consulting all stakeholders on the market is impractical; thus many companies utilize indirect data sources, e.g. documents and representatives of larger groups of stakeholders. However, companies often collect irrelevant data or develop their products based on the sub-optimal information sources that may lead to missing market opportunities. Objectives: We propose a collaborative method for identification and selection of data sources. The method consists of four steps and aims to build consensus between different perspectives in an organization. Methods: We develop the method following the design science research method. We demonstrate the use of the method with three industrial case studies. Results: Our results show that the method can support the identification and selection of data sources in three ways: (1) by providing systematic steps to identify and prioritize data sources for RE, (2) by highlighting and resolving discrepancies between different perspectives in an organization, and (3) by analyzing the underlying rationale for using certain data sources. Conclusion: We conclude that our proposed method is well suited to support systematic identification of requirements sources in industry. Further work on the method include validation and adaptation for use different contexts, and developing tool support.
- Published
- 2022
4. A Method for Identification and Ranking of Requirements Sources
- Author
-
Sub Organization and Information, Organization and Information, Klotins, E., Boeva, V., Wnuk, Krzysztof, Unterkalmsteiner, M., Gorschek, T., Jansen, S., Sub Organization and Information, Organization and Information, Klotins, E., Boeva, V., Wnuk, Krzysztof, Unterkalmsteiner, M., Gorschek, T., and Jansen, S.
- Published
- 2022
5. Informations technologie in organisations management systemen (on the example of the federal penetentiary service of Russia)
- Author
-
Novruzova, V. E., Boeva, V. V., and Bulgakova, I. V.
- Subjects
MATHEMATICAL MODELING ,INFORMATION TECHNOLOGIES ,COMPUTER TECHNOLOGIES ,КОМПЬЮТЕРНЫЕ ТЕХНОЛОГИИ ,АВТОМАТИЗИРОВАННЫЕ ИНФОРМАЦИОННЫЕ СИСТЕМЫ ИНТЕЛЛЕКТУАЛЬНОГО ТИПА ,AUTOMATED INFORMATION SYSTEMS OF INTELLECTUAL TYPE ,МАТЕМАТИЧЕСКОЕ МОДЕЛИРОВАНИЕ ,ИНФОРМАЦИОННЫЕ ТЕХНОЛОГИИ - Abstract
Статья посвящена рассмотрению преимуществ применения компьютерных технологий в принятии управленческих решений в деятельности предприятий. В статье раскрываются основные технические достижения, лежащие в основе современных информационных технологий, делается попытка охарактеризовать особенности применения автоматизированной обработки данных в организационных системах на примере Федеральной службы исполнения наказаний России. Авторы статьи анализируют трудности реализации математических методов моделирования в сфере экономики. The article deals with the consideration of advantages of computer technologies’ using in making managerial decisions in the enterprises’ activities. The article reveals the main technical achievements underlying modern information technologies and an attempt is made to characterize the features of the use of automated data processing in organizational systems on the exemple of the Federal Penitentiary Service of Russia. The authors of the article analyze the difficulties of implementing mathematical modeling methods in the field of economics.
- Published
- 2022
6. Synthesis of a smoothing bicubic spline for differentiating experimental data of nonparametric identification
- Author
-
Voskoboinikov, Yu, primary and Boeva, V, additional
- Published
- 2021
- Full Text
- View/download PDF
7. Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy
- Author
-
Chen, J, Nelson, C, Wong, M, Tee, AE, Liu, PY, La, T, Fletcher, JI, Kamili, A, Mayoh, C, Bartenhagen, C, Trahair, TN, Xu, N, Jayatilleke, N, Peng, H, Atmadibrata, B, Cheung, BB, Lan, Q, Bryan, TM, Mestdagh, P, Vandesompele, J, Combaret, V, Boeva, V, Wang, JY, Janoueix-Lerosey, I, Cowley, MJ, MacKenzie, KL, Dolnikov, A, Li, J, Polly, P, Marshall, GM, Reddel, RR, Norris, MD, Haber, M, Fischer, M, Zhang, XD, Pickett, HA, and Liu, T
- Subjects
1112 Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeTERT gene rearrangement with transcriptional superenhancers leads to TERT overexpression and neuroblastoma. No targeted therapy is available for clinical trials in patients with TERT-rearranged neuroblastoma.Experimental designAnticancer agents exerting the best synergistic anticancer effects with BET bromodomain inhibitors were identified by screening an FDA-approved oncology drug library. The synergistic effects of the BET bromodomain inhibitor OTX015 and the proteasome inhibitor carfilzomib were examined by immunoblot and flow cytometry analysis. The anticancer efficacy of OTX015 and carfilzomib combination therapy was investigated in mice xenografted with TERT-rearranged neuroblastoma cell lines or patient-derived xenograft (PDX) tumor cells, and the role of TERT reduction in the anticancer efficacy was examined through rescue experiments in mice.ResultsThe BET bromodomain protein BRD4 promoted TERT-rearranged neuroblastoma cell proliferation through upregulating TERT expression. Screening of an approved oncology drug library identified the proteasome inhibitor carfilzomib as the agent exerting the best synergistic anticancer effects with BET bromodomain inhibitors including OTX015. OTX015 and carfilzomib synergistically reduced TERT protein expression, induced endoplasmic reticulum stress, and induced TERT-rearranged neuroblastoma cell apoptosis which was blocked by TERT overexpression and endoplasmic reticulum stress antagonists. In mice xenografted with TERT-rearranged neuroblastoma cell lines or PDX tumor cells, OTX015 and carfilzomib synergistically blocked TERT expression, induced tumor cell apoptosis, suppressed tumor progression, and improved mouse survival, which was largely reversed by forced TERT overexpression.ConclusionsOTX015 and carfilzomib combination therapy is likely to be translated into the first clinical trial of a targeted therapy in patients with TERT-rearranged neuroblastoma.
- Published
- 2020
8. Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy
- Author
-
Chen, J ; https://orcid.org/0000-0002-6774-0199, Nelson, C, Wong, M ; https://orcid.org/0000-0002-0324-8664, Tee, AE, Liu, PY ; https://orcid.org/0000-0001-9237-5990, La, T, Fletcher, JI ; https://orcid.org/0000-0003-2949-9469, Kamili, A ; https://orcid.org/0000-0002-4864-1195, Mayoh, C ; https://orcid.org/0000-0002-6398-3046, Bartenhagen, C, Trahair, TN ; https://orcid.org/0000-0002-3295-228X, Xu, N, Jayatilleke, N ; https://orcid.org/0000-0003-4086-0622, Wong, M, Peng, H, Atmadibrata, B, Cheung, BB ; https://orcid.org/0000-0001-8784-860X, Lan, Q, Bryan, TM, Mestdagh, P, Vandesompele, J, Combaret, V, Boeva, V, Wang, JY ; https://orcid.org/0000-0002-1325-7943, Janoueix-Lerosey, I, Cowley, MJ ; https://orcid.org/0000-0002-9519-5714, MacKenzie, KL, Dolnikov, A, Li, J, Polly, P ; https://orcid.org/0000-0001-7250-5217, Marshall, GM, Reddel, RR, Norris, MD ; https://orcid.org/0000-0002-0632-4589, Haber, M ; https://orcid.org/0000-0003-2036-8817, Fischer, M, Zhang, XD, Pickett, HA, Liu, T ; https://orcid.org/0000-0001-6244-7316, Chen, J ; https://orcid.org/0000-0002-6774-0199, Nelson, C, Wong, M ; https://orcid.org/0000-0002-0324-8664, Tee, AE, Liu, PY ; https://orcid.org/0000-0001-9237-5990, La, T, Fletcher, JI ; https://orcid.org/0000-0003-2949-9469, Kamili, A ; https://orcid.org/0000-0002-4864-1195, Mayoh, C ; https://orcid.org/0000-0002-6398-3046, Bartenhagen, C, Trahair, TN ; https://orcid.org/0000-0002-3295-228X, Xu, N, Jayatilleke, N ; https://orcid.org/0000-0003-4086-0622, Wong, M, Peng, H, Atmadibrata, B, Cheung, BB ; https://orcid.org/0000-0001-8784-860X, Lan, Q, Bryan, TM, Mestdagh, P, Vandesompele, J, Combaret, V, Boeva, V, Wang, JY ; https://orcid.org/0000-0002-1325-7943, Janoueix-Lerosey, I, Cowley, MJ ; https://orcid.org/0000-0002-9519-5714, MacKenzie, KL, Dolnikov, A, Li, J, Polly, P ; https://orcid.org/0000-0001-7250-5217, Marshall, GM, Reddel, RR, Norris, MD ; https://orcid.org/0000-0002-0632-4589, Haber, M ; https://orcid.org/0000-0003-2036-8817, Fischer, M, Zhang, XD, Pickett, HA, and Liu, T ; https://orcid.org/0000-0001-6244-7316
- Abstract
Purpose: TERT gene rearrangement with transcriptional superenhancers leads to TERT overexpression and neuroblastoma. No targeted therapy is available for clinical trials in patients with TERT-rearranged neuroblastoma. Experimental Design: Anticancer agents exerting the best synergistic anticancer effects with BET bromodomain inhibitors were identified by screening an FDA-approved oncology drug library. The synergistic effects of the BET bromodomain inhibitor OTX015 and the proteasome inhibitor carfilzomib were examined by immunoblot and flow cytometry analysis. The anticancer efficacy of OTX015 and carfilzomib combination therapy was investigated in mice xenografted with TERT-rearranged neuroblastoma cell lines or patient-derived xenograft (PDX) tumor cells, and the role of TERT reduction in the anticancer efficacy was examined through rescue experiments in mice. Results: The BET bromodomain protein BRD4 promoted TERT-rearranged neuroblastoma cell proliferation through upregulating TERT expression. Screening of an approved oncology drug library identified the proteasome inhibitor carfilzomib as the agent exerting the best synergistic anticancer effects with BET bromodomain inhibitors including OTX015. OTX015 and carfilzomib synergistically reduced TERT protein expression, induced endoplasmic reticulum stress, and induced TERT-rearranged neuroblastoma cell apoptosis which was blocked by TERT overexpression and endoplasmic reticulum stress antagonists. In mice xenografted with TERT-rearranged neuroblastoma cell lines or PDX tumor cells, OTX015 and carfilzomib synergistically blocked TERT expression, induced tumor cell apoptosis, suppressed tumor progression, and improved mouse survival, which was largely reversed by forced TERT overexpression. Conclusions: OTX015 and carfilzomib combination therapy is likely to be translated into the first clinical trial of a targeted therapy in patients with TERT-rearranged neuroblastoma.
- Published
- 2021
9. Energy-aware very fast decision tree
- Author
-
García-Martín, E., Lavesson, Niklas, Grahn, H., Casalicchio, E., Boeva, V., García-Martín, E., Lavesson, Niklas, Grahn, H., Casalicchio, E., and Boeva, V.
- Abstract
Recently machine learning researchers are designing algorithms that can run in embedded and mobile devices, which introduces additional constraints compared to traditional algorithm design approaches. One of these constraints is energy consumption, which directly translates to battery capacity for these devices. Streaming algorithms, such as the Very Fast Decision Tree (VFDT), are designed to run in such devices due to their high velocity and low memory requirements. However, they have not been designed with an energy efficiency focus. This paper addresses this challenge by presenting the nmin adaptation method, which reduces the energy consumption of the VFDT algorithm with only minor effects on accuracy. nmin adaptation allows the algorithm to grow faster in those branches where there is more confidence to create a split, and delays the split on the less confident branches. This removes unnecessary computations related to checking for splits but maintains similar levels of accuracy. We have conducted extensive experiments on 29 public datasets, showing that the VFDT with nmin adaptation consumes up to 31% less energy than the original VFDT, and up to 96% less energy than the CVFDT (VFDT adapted for concept drift scenarios), trading off up to 1.7 percent of accuracy.
- Published
- 2021
- Full Text
- View/download PDF
10. Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy.
- Author
-
Chen, J, Nelson, C, Wong, M, Tee, AE, Liu, PY, La, T, Fletcher, JI, Kamili, A, Mayoh, C, Bartenhagen, C, Trahair, TN, Xu, N, Jayatilleke, N, Peng, H, Atmadibrata, B, Cheung, BB, Lan, Q, Bryan, TM, Mestdagh, P, Vandesompele, J, Combaret, V, Boeva, V, Wang, JY, Janoueix-Lerosey, I, Cowley, MJ, MacKenzie, KL, Dolnikov, A, Li, J, Polly, P, Marshall, GM, Reddel, RR, Norris, MD, Haber, M, Fischer, M, Zhang, XD, Pickett, HA, Liu, T, Chen, J, Nelson, C, Wong, M, Tee, AE, Liu, PY, La, T, Fletcher, JI, Kamili, A, Mayoh, C, Bartenhagen, C, Trahair, TN, Xu, N, Jayatilleke, N, Peng, H, Atmadibrata, B, Cheung, BB, Lan, Q, Bryan, TM, Mestdagh, P, Vandesompele, J, Combaret, V, Boeva, V, Wang, JY, Janoueix-Lerosey, I, Cowley, MJ, MacKenzie, KL, Dolnikov, A, Li, J, Polly, P, Marshall, GM, Reddel, RR, Norris, MD, Haber, M, Fischer, M, Zhang, XD, Pickett, HA, and Liu, T
- Abstract
Purpose
TERT gene rearrangement with transcriptional superenhancers leads to TERT overexpression and neuroblastoma. No targeted therapy is available for clinical trials in patients with TERT-rearranged neuroblastoma.Experimental design
Anticancer agents exerting the best synergistic anticancer effects with BET bromodomain inhibitors were identified by screening an FDA-approved oncology drug library. The synergistic effects of the BET bromodomain inhibitor OTX015 and the proteasome inhibitor carfilzomib were examined by immunoblot and flow cytometry analysis. The anticancer efficacy of OTX015 and carfilzomib combination therapy was investigated in mice xenografted with TERT-rearranged neuroblastoma cell lines or patient-derived xenograft (PDX) tumor cells, and the role of TERT reduction in the anticancer efficacy was examined through rescue experiments in mice.Results
The BET bromodomain protein BRD4 promoted TERT-rearranged neuroblastoma cell proliferation through upregulating TERT expression. Screening of an approved oncology drug library identified the proteasome inhibitor carfilzomib as the agent exerting the best synergistic anticancer effects with BET bromodomain inhibitors including OTX015. OTX015 and carfilzomib synergistically reduced TERT protein expression, induced endoplasmic reticulum stress, and induced TERT-rearranged neuroblastoma cell apoptosis which was blocked by TERT overexpression and endoplasmic reticulum stress antagonists. In mice xenografted with TERT-rearranged neuroblastoma cell lines or PDX tumor cells, OTX015 and carfilzomib synergistically blocked TERT expression, induced tumor cell apoptosis, suppressed tumor progression, and improved mouse survival, which was largely reversed by forced TERT overexpression.Conclusions
OTX015 and carfilzomib combination therapy is likely to be translated into the first clinical trial of a targeted therapy in patients with- Published
- 2021
11. Relationship of micro-and minisatellites in the human genome
- Author
-
Boeva, V. A., Fridman, M. V., and Makeev, V. Yu.
- Published
- 2006
- Full Text
- View/download PDF
12. Synthesis of smoothing cubic spline in non-parametric identification technical systems’ algorithm
- Author
-
Voskoboinikov, Y, primary and Boeva, V, additional
- Published
- 2020
- Full Text
- View/download PDF
13. Deep and wide digging for binding motifs in ChIP-Seq data
- Author
-
Kulakovskiy, I. V., Boeva, V. A., Favorov, A. V., and Makeev, V. J.
- Published
- 2010
- Full Text
- View/download PDF
14. Transcriptional programs define intratumoral heterogeneity of Ewing sarcoma at single cell resolution
- Author
-
Aynaud, M-M, primary, Mirabeau, O, additional, Gruel, N, additional, Grossetête, S, additional, Boeva, V, additional, Durand, S, additional, Surdez, D, additional, Saulnier, O, additional, Zaïdi, S, additional, Gribkova, S, additional, Kairov, U, additional, Raynal, V, additional, Tirode, F, additional, Grünewald, TGP, additional, Bohec, M, additional, Baulande, S, additional, Janoueix-Lerosey, I, additional, Vert, J-P, additional, Barillot, E, additional, Delattre, O, additional, and Zinovyev, A, additional
- Published
- 2019
- Full Text
- View/download PDF
15. Higher order mining for monitoring district heating substations
- Author
-
Abghari, S., Boeva, V., Brage, J., Johansson, C., Grahn, H., Lavesson, Niklas, Abghari, S., Boeva, V., Brage, J., Johansson, C., Grahn, H., and Lavesson, Niklas
- Abstract
We propose a higher order mining (HOM) approach for modelling, monitoring and analyzing district heating (DH) substations' operational behaviour and performance. HOM is concerned with mining over patterns rather than primary or raw data. The proposed approach uses a combination of different data analysis techniques such as sequential pattern mining, clustering analysis, consensus clustering and minimum spanning tree (MST). Initially, a substation's operational behaviour is modeled by extracting weekly patterns and performing clustering analysis. The substation's performance is monitored by assessing its modeled behaviour for every two consecutive weeks. In case some significant difference is observed, further analysis is performed by integrating the built models into a consensus clustering and applying an MST for identifying deviating behaviours. The results of the study show that our method is robust for detecting deviating and sub-optimal behaviours of DH substations. In addition, the proposed method can facilitate domain experts in the interpretation and understanding of the substations' behaviour and performance by providing different data analysis and visualization techniques., Funding details: Stiftelsen för Kunskaps- och Kompetensutveckling, KK, 201400This work is part of the research project “Scalable resource-efficient systems for big data analytics“ funded by the Knowledge Foundation (grant: 20140032) in Sweden.
- Published
- 2019
- Full Text
- View/download PDF
16. Data Descriptor: Meta-mining of copy number profiles of high-risk neuroblastoma tumors
- Author
-
Depuydt, Pauline, Koster, J, Boeva, V, Hocking, TD, Speleman, Franki, Schleiermacher, G, and De Preter, Katleen
- Subjects
AGE ,MUTATIONS ,Biology and Life Sciences - Abstract
Neuroblastoma, a pediatric tumor of the sympathetic nervous system, is predominantly driven by copy number aberrations, which predict survival outcome in global neuroblastoma cohorts and in low-risk cases. For high-risk patients there is still a need for better prognostic biomarkers. Via an international collaboration, we collected copy number profiles of 556 high-risk neuroblastomas generated on different array platforms. This manuscript describes the composition of the dataset, the methods used to process the data, including segmentation and aberration calling, and data validation. t-SNE analysis shows that samples cluster according to MYCN status, and shows a difference between array platforms. 97.3% of samples are characterized by the presence of segmental aberrations, in regions frequently affected in neuroblastoma. Focal aberrations affect genes known to be involved in neuroblastoma, such as ALK and L1N288. To conclude, we compiled a unique large copy number dataset of high-risk neuroblastoma tumors, available via R2 and a Shiny web application. The availability of patient survival data allows to further investigate the prognostic value of copy number aberrations.
- Published
- 2018
17. EUFOREA Rhinology Research Forum 2017: report of the brainstorming sessions on endotype-driven treatment, patient empowerment and digital future in airways care
- Author
-
Lund, V.J., primary, Hopkins, C., additional, Akdis, C., additional, Bachert, C., additional, Bousquet, J., additional, Fokkens, W.J., additional, Seys, S., additional, Van Gerven, L., additional, Akdis, M., additional, Ban, G.Y., additional, Biswas, K., additional, Boscke, R., additional, Boeva, V., additional, Canonica, G.W., additional, Castillo, J.A., additional, Chung, S.K., additional, Claes, J.A.M., additional, Cools, L., additional, De Carlo, G., additional, De Corso, E., additional, Djandji, M., additional, Doulaptsi, M., additional, Feijen, J., additional, Gallo, S., additional, Gane, S., additional, Gevaert, P., additional, Golebski, K., additional, Halewyck, S., additional, Hummel, T., additional, Izquierdo, I., additional, Jagerschmidt, A., additional, Joos, G.F., additional, Kjeldsen, A.D., additional, Kloeck, I., additional, Koennecke, M., additional, Kokorina, O., additional, Koren, I., additional, Kortekaas-Krohn, I., additional, Krysko, O., additional, Landis, B.N., additional, Lange, B., additional, Launders, N., additional, Lee, J., additional, Lekakis, G., additional, Mannent, L., additional, Martens, K., additional, Morghenti, D., additional, Mullol, J., additional, Murray, R., additional, O'Sullivan, D., additional, Philpott, C., additional, Popov, T.A., additional, Prokopakis, E., additional, Rombaux, P., additional, Rondon, C., additional, Rowe, P.J., additional, Seyed-Tabib, N.S., additional, Sleurs, K., additional, Speleman, K.J.S., additional, Staikuniene, J., additional, Steelant, B., additional, Talavera-Perez, K., additional, Taube, C., additional, Toppila-Salmi, S., additional, Tran-Le, T., additional, Vaitkus, J., additional, Vaitkus, S., additional, Van Gool, K., additional, Van Hoolst, A., additional, Verbrugge, R., additional, Verhaeghe, B., additional, Vlaminck, S., additional, Wagenmann, M., additional, Zuberbier, T., additional, Tasman, A.-J., additional, Pugin, B., additional, and Hellings, P.W., additional
- Published
- 2018
- Full Text
- View/download PDF
18. Computational pan-genomics: Status, promises and challenges
- Author
-
Marschall, T. (Tanja), Marz, M. (Manja), Abeel, T. (Thomas), Dijkstra, L. (Louis), Dutilh, B.E. (Bas), Ghaffaari, A. (Ali), Kersey, P. (Paul), Kloosterman, W.P. (Wigard), Mäkinen, V. (Veli), Novak, A.M. (Adam M.), Paten, B. (Benedict), Porubsky, D. (David), Rivals, E. (Eric), Alkan, C. (Can), Baaijens, J.A. (Jasmijn A.), Bakker, P.I.W. (Paul) de, Boeva, V. (Valentina), Bonnal, R.J.P. (Raoul J.P.), Chiaromonte, F. (Francesca), Chikhi, R. (Rayan), Ciccarelli, F.D. (Francesca D.), Cijvat, R. (Robin), Datema, E. (Erwin), Duijn, C.M. (Cornelia) van, Eichler, E.E. (Evan), Ernst, C. (Corinna), Eskin, E. (E.), Garrison, E. (Erik), El-Kebir, M. (Mohammed), Klau, G.W. (Gunnar W.), Korbel, J.O. (Jan), Lameijer, E.-W. (Eric-Wubbo), Langmead, B. (Benjamin), Martin, M. (Marcel), Medvedev, P. (Paul), Mu, J.C. (John C.), Neerincx, P.B.T. (Pieter B T), Ouwens, K. (Klaasjan), Peterlongo, P. (Pierre), Pisanti, N. (Nadia), Rahmann, S. (S.), Raphael, B.J. (Benjamin J.), Reinert, K. (Knut), Ridder, D. (Dick) de, de Ridder, J. (Jeroen), Schlesner, M. (Matthias), Schulz-Trieglaff, O. (Ole), Sanders, A.D. (Ashley D.), Sheikhizadeh, S. (Siavash), Shneider, C. (Carl), Smit, S. (Sandra), Valenzuela, D. (Daniel), Wang, J. (Jiayin), Wessels, L. (Lodewyk), Zhang, Y. (Ying), Guryev, V. (Victor), Vandin, F. (Fabio), Ye, K. (Kai), Schönhuth, A. (Alexander), Marschall, T. (Tanja), Marz, M. (Manja), Abeel, T. (Thomas), Dijkstra, L. (Louis), Dutilh, B.E. (Bas), Ghaffaari, A. (Ali), Kersey, P. (Paul), Kloosterman, W.P. (Wigard), Mäkinen, V. (Veli), Novak, A.M. (Adam M.), Paten, B. (Benedict), Porubsky, D. (David), Rivals, E. (Eric), Alkan, C. (Can), Baaijens, J.A. (Jasmijn A.), Bakker, P.I.W. (Paul) de, Boeva, V. (Valentina), Bonnal, R.J.P. (Raoul J.P.), Chiaromonte, F. (Francesca), Chikhi, R. (Rayan), Ciccarelli, F.D. (Francesca D.), Cijvat, R. (Robin), Datema, E. (Erwin), Duijn, C.M. (Cornelia) van, Eichler, E.E. (Evan), Ernst, C. (Corinna), Eskin, E. (E.), Garrison, E. (Erik), El-Kebir, M. (Mohammed), Klau, G.W. (Gunnar W.), Korbel, J.O. (Jan), Lameijer, E.-W. (Eric-Wubbo), Langmead, B. (Benjamin), Martin, M. (Marcel), Medvedev, P. (Paul), Mu, J.C. (John C.), Neerincx, P.B.T. (Pieter B T), Ouwens, K. (Klaasjan), Peterlongo, P. (Pierre), Pisanti, N. (Nadia), Rahmann, S. (S.), Raphael, B.J. (Benjamin J.), Reinert, K. (Knut), Ridder, D. (Dick) de, de Ridder, J. (Jeroen), Schlesner, M. (Matthias), Schulz-Trieglaff, O. (Ole), Sanders, A.D. (Ashley D.), Sheikhizadeh, S. (Siavash), Shneider, C. (Carl), Smit, S. (Sandra), Valenzuela, D. (Daniel), Wang, J. (Jiayin), Wessels, L. (Lodewyk), Zhang, Y. (Ying), Guryev, V. (Victor), Vandin, F. (Fabio), Ye, K. (Kai), and Schönhuth, A. (Alexander)
- Abstract
Many disciplines, from human genetics and oncology to plant breeding, microbiology and virology, commonly face the challenge of analyzing rapidly increasing numbers of genomes. In case of Homo sapiens, the number of sequenced genomes will approach hundreds of thousands in the next few years. Simply scaling up established bioinformatics pipelines will not be sufficient for leveraging the full potential of such rich genomic data sets. Instead, novel, qualitatively different Computational methods and paradigms are needed.We will witness the rapid extension of Computational pan-genomics, a new sub-area of research in Computational biology. In this article, we generalize existing definitions and understand a pangenome as any collection of genomic sequences to be analyzed jointly or to be used as a reference. We examine already available approaches to construct and use pan-genomes, discuss the potential benefits of future technologies and methodologies and review open challenges from the vantage point of the above-mentioned biological disciplines. As a prominent example for a Computational paradigm shift, we particularly highlight the transition from the representation of reference genomes as strings to representations a
- Published
- 2018
- Full Text
- View/download PDF
19. Computational pan-genomics: status, promises and challenges.
- Author
-
Marschall, T., Marz, M., Abeel, T., Dijkstra, L., Dutilh, B.E., Ghaffaari, A., Kersey, P., Kloosterman, W.P., Mäkinen, V., Novak, A.M., Paten, B., Porubsky, D., Rivals, E., Alkan, C., Baaijens, J., Bakker, P.I. de, Boeva, V., Bonnal, R.J., Chiaromonte, F., Chikhi, R., Ciccarelli, F.D., Cijvat, R., Datema, E., Duijn, C.M. van, Eichler, E.E., Ernst, C., Eskin, E., Garrison, E., El-Kebir, M., Klau, G.W., Korbel, J.O., Lameijer, E.W., Langmead, B., Martin, M., Medvedev, P., Mu, J.C., Neerincx, P., Ouwens, K., Peterlongo, P., Pisanti, N., Rahmann, S., Raphael, B., Reinert, K., Ridder, D. de, Ridder, J. de, Schlesner, M., Schulz-Trieglaff, O., Sanders, A.D., Sheikhizadeh, S., Shneider, C., Smit, S., Valenzuela, D., Wang, J, Wessels, L., Zhang, Y, Guryev, V., Vandin, F., Ye, K., Schönhuth, A., Marschall, T., Marz, M., Abeel, T., Dijkstra, L., Dutilh, B.E., Ghaffaari, A., Kersey, P., Kloosterman, W.P., Mäkinen, V., Novak, A.M., Paten, B., Porubsky, D., Rivals, E., Alkan, C., Baaijens, J., Bakker, P.I. de, Boeva, V., Bonnal, R.J., Chiaromonte, F., Chikhi, R., Ciccarelli, F.D., Cijvat, R., Datema, E., Duijn, C.M. van, Eichler, E.E., Ernst, C., Eskin, E., Garrison, E., El-Kebir, M., Klau, G.W., Korbel, J.O., Lameijer, E.W., Langmead, B., Martin, M., Medvedev, P., Mu, J.C., Neerincx, P., Ouwens, K., Peterlongo, P., Pisanti, N., Rahmann, S., Raphael, B., Reinert, K., Ridder, D. de, Ridder, J. de, Schlesner, M., Schulz-Trieglaff, O., Sanders, A.D., Sheikhizadeh, S., Shneider, C., Smit, S., Valenzuela, D., Wang, J, Wessels, L., Zhang, Y, Guryev, V., Vandin, F., Ye, K., and Schönhuth, A.
- Abstract
Contains fulltext : 190288.pdf (publisher's version ) (Open Access)
- Published
- 2018
20. Computational pan-genomics: status, promises and challenges
- Author
-
Marschall, T, Marz, M, Abeel, T, Dijkstra, L, Dutilh, BE, Ghaffaari, A, Kersey, P, Kloosterman, WP, Makinen, V, Novak, AM, Paten, B, Porubsky, D, Rivals, E, Alkan, C, Baaijens, J A, de Bakker, PIW, Boeva, V, Bonnal, RJP, Chiaromonte, F, Chikhi, R, Ciccarelli, FD, Cijvat, R, Datema, E, Duijn, Cornelia, Eichler, EE, Ernst, C, Eskin, E, Garrison, E, El-Kebir, M, Klau, GW, Korbel, JO, Lameijer, EW, Langmead, B, Martin, M, Medvedev, P, Mu, JC, Neerincx, P, Ouwens, K, Peterlongo, P, Pisanti, N, Rahmann, S, Raphael, B, Reinert, K, Ridder, D, Ridder, J (Jannemarie), Schlesner, M, Schulz-Trieglaff, O, Sanders, AD, Sheikhizadeh, S, Shneider, C, Smit, S, Valenzuela, D, Wang, JY, Wessels, L, Zhang, Y, Guryev, V, Vandin, F, Ye, K, Schonhuth, A, Marschall, T, Marz, M, Abeel, T, Dijkstra, L, Dutilh, BE, Ghaffaari, A, Kersey, P, Kloosterman, WP, Makinen, V, Novak, AM, Paten, B, Porubsky, D, Rivals, E, Alkan, C, Baaijens, J A, de Bakker, PIW, Boeva, V, Bonnal, RJP, Chiaromonte, F, Chikhi, R, Ciccarelli, FD, Cijvat, R, Datema, E, Duijn, Cornelia, Eichler, EE, Ernst, C, Eskin, E, Garrison, E, El-Kebir, M, Klau, GW, Korbel, JO, Lameijer, EW, Langmead, B, Martin, M, Medvedev, P, Mu, JC, Neerincx, P, Ouwens, K, Peterlongo, P, Pisanti, N, Rahmann, S, Raphael, B, Reinert, K, Ridder, D, Ridder, J (Jannemarie), Schlesner, M, Schulz-Trieglaff, O, Sanders, AD, Sheikhizadeh, S, Shneider, C, Smit, S, Valenzuela, D, Wang, JY, Wessels, L, Zhang, Y, Guryev, V, Vandin, F, Ye, K, and Schonhuth, A
- Published
- 2018
21. The influence of the vitamin D3 level in the blood serum of lactase gene polymorphism on the development of chronic polypous rhinosinusitis
- Author
-
Boeva, V. I., primary, Kokorina, O. V., additional, Archba, R. R., additional, Dvoryanchikov, V. V., additional, and Kolhyubaeva, S. N., additional
- Published
- 2018
- Full Text
- View/download PDF
22. Peer Review #1 of "Effect of method of deduplication on estimation of differential gene expression using RNA-seq (v0.2)"
- Author
-
Boeva, V, additional
- Published
- 2017
- Full Text
- View/download PDF
23. Human echinococcosis in Bulgaria: a comparative epidemiological analysis(*)
- Author
-
Todorov, T. and Boeva, V.
- Subjects
Bulgaria -- Health aspects ,Statistics ,Health aspects ,Echinococcosis -- Statistics -- Health aspects - Abstract
Voir page 116 le resume en francais. En la pagina 117 figura un resumen en espanol. Background Bulgaria occupies some 110 000 [km.sup.2] of the eastern portion of the Balkan [...], The present article describes the importance of human echinococcosis as a public health problem in Bulgaria, outlines the control measures carried out and evaluates comparatively the situation over three periods spanning 46 years (1950-1995). During the first period (1950-62), a total of 6469 new surgically confirmed cases of hydatid disease were recorded in Bulgaria, with an annual incidence of 6.5 per 100 000 population, and the infestation rate in domestic animals and dogs was high. Echinococcosis was endemic throughout the country. The organization of a control campaign, initiated in 1960, led to a considerable improvement in the situation during the second period (1971-82). Morbidity among humans gradually decreased, with an average incidence of 2.0 per 100 000, and the proportion of infected animals also fell. The distribution of echinococcosis was characterized as sporadic or of low endemicity. During the third period (1983-95), owing to administrative irregularities and economic changes, funds for supporting the campaign were reduced and control structures were dismantled. As a result, the incidence rose to 3.3 per 100 000. Echinococcosis again became endemic, in some regions hyperendemic. The findings provide convincing evidence that cessation of control measures or reduction of campaign activity can lead to intensification in the transmission of Echinococcus granulosus and to a resurgence in echinococcosis to previous levels.
- Published
- 1999
24. 575 Detection of Genes and Pathways Involved in the Development of Aggressive Neuroblastoma Using Genome Copy Number Data
- Author
-
Boeva, V., primary, Hocking, T.D., additional, Schleiermacher, G., additional, Janoueix-Lerosey, I., additional, Delattre, O., additional, and Barillot, E., additional
- Published
- 2012
- Full Text
- View/download PDF
25. Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling
- Author
-
Kerdivel, G, Chesnais, V, Becht, E, Toma, A, Cagnard, N, Dumont, F, Rousseau, A, Fenaux, P, Chevret, S, Chapuis, N, Boeva, V, Fridman, W H, Fontenay, M, and Kosmider, O
- Published
- 2018
- Full Text
- View/download PDF
26. A transition logic for schemata conflicts
- Author
-
Boeva, V, Ekenberg, Love, Boeva, V, and Ekenberg, Love
- Abstract
Conflict detection and analysis are of high importance, e.g., when integrating conceptual schemata, such as UML-Specifications, or analysing goal-fulfilment of sets of autonomous agents. In general, models for this introduce unnecessarily complicated frameworks with several disadvantages regarding semantics as well as complexity. This paper demonstrates that an important set of static and dynamic conflicts between specifications can be diagnosed using ordinary first-order modal logic. Furthermore, we show how the framework can be extended for handling situations when there are convex sets of probability measures over a state-space. Thus, representing specifications as conceptual schemata and using standard Kripke models of modal logic, augmented with an interval-valued probability measure, we propose instrumental definitions and procedures for conflict detection., QC 20110921
- Published
- 2004
- Full Text
- View/download PDF
27. 828 Ewing sarcoma network model through EWS-FLI1 signaling
- Author
-
Stoll, G., primary, Surdez, D., additional, Tirode, F., additional, Laud-Duval, K., additional, Guillon, N., additional, Boeva, V., additional, Delattre, O., additional, Barillot, E., additional, and Zinovyev, A., additional
- Published
- 2010
- Full Text
- View/download PDF
28. A hybrid computational method for the identification of cell cycle-regulated genes.
- Author
-
Boeva, V., Ivanova, P., and Lavesson, N.
- Published
- 2010
- Full Text
- View/download PDF
29. A Collaborative Decision Support Platform for Product Release Definition.
- Author
-
Tsiporkova, E., Tourwe?, T., and Boeva, V.
- Published
- 2010
- Full Text
- View/download PDF
30. A Hybrid DTW Based Method for Integration Analysis of Time Series Data.
- Author
-
Boeva, V. and Kostadinova, E.
- Published
- 2009
- Full Text
- View/download PDF
31. A novel gene-centric clustering algorithm for standardization of time series expression data.
- Author
-
Tsiporkova, E. and Boeva, V.
- Published
- 2008
- Full Text
- View/download PDF
32. Echinococcosis in children and adolescents in Bulgaria: a comparative study
- Author
-
Todorov, T., primary and Boeva, V., additional
- Published
- 2000
- Full Text
- View/download PDF
33. Epidemiological characteristics of trichinellosis in Bulgaria
- Author
-
Todorov, T., primary and Boeva, V., additional
- Published
- 1998
- Full Text
- View/download PDF
34. Electrokinetic Supply of Nutrients in Soil Bioremediation
- Author
-
Elektorowicz, M., primary and Boeva, V., additional
- Published
- 1996
- Full Text
- View/download PDF
35. Dempster-Shafer theory framed in modal logic
- Author
-
Tsiporkova, E., Boeva, V., and Baets, B. De
- Published
- 1999
- Full Text
- View/download PDF
36. Dempster's rule of conditioning translated into modal logic
- Author
-
Tsiporkova, E., Baets, B. De, and Boeva, V.
- Published
- 1999
- Full Text
- View/download PDF
37. Decision analysis based on Kripke's semantics
- Author
-
Boeva, V., primary and Ekenberg, L., additional
- Full Text
- View/download PDF
38. Exact p-value calculation for heterotypic clusters of regulatory motifs and its application in computational annotation of cis-regulatory modules
- Author
-
Roytberg Mikhail A, Régnier Mireille, Clément Julien, Boeva Valentina, and Makeev Vsevolod J
- Subjects
Biology (General) ,QH301-705.5 ,Genetics ,QH426-470 - Abstract
Abstract Background cis-Regulatory modules (CRMs) of eukaryotic genes often contain multiple binding sites for transcription factors. The phenomenon that binding sites form clusters in CRMs is exploited in many algorithms to locate CRMs in a genome. This gives rise to the problem of calculating the statistical significance of the event that multiple sites, recognized by different factors, would be found simultaneously in a text of a fixed length. The main difficulty comes from overlapping occurrences of motifs. So far, no tools have been developed allowing the computation of p-values for simultaneous occurrences of different motifs which can overlap. Results We developed and implemented an algorithm computing the p-value that s different motifs occur respectively k1, ..., ks or more times, possibly overlapping, in a random text. Motifs can be represented with a majority of popular motif models, but in all cases, without indels. Zero or first order Markov chains can be adopted as a model for the random text. The computational tool was tested on the set of cis-regulatory modules involved in D. melanogaster early development, for which there exists an annotation of binding sites for transcription factors. Our test allowed us to correctly identify transcription factors cooperatively/competitively binding to DNA. Method The algorithm that precisely computes the probability of simultaneous motif occurrences is inspired by the Aho-Corasick automaton and employs a prefix tree together with a transition function. The algorithm runs with the O(n|Σ|(m|ℋ MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaat0uy0HwzTfgDPnwy1egaryqtHrhAL1wy0L2yHvdaiqaacqWFlecsaaa@3762@| + K|σ|K) ∏i ki) time complexity, where n is the length of the text, |Σ| is the alphabet size, m is the maximal motif length, |ℋ MathType@MTEF@5@5@+=feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY=wiFfYdH8Gipec8Eeeu0xXdbba9frFj0=OqFfea0dXdd9vqai=hGuQ8kuc9pgc9s8qqaq=dirpe0xb9q8qiLsFr0=vr0=vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaat0uy0HwzTfgDPnwy1egaryqtHrhAL1wy0L2yHvdaiqaacqWFlecsaaa@3762@| is the total number of words in motifs, K is the order of Markov model, and ki is the number of occurrences of the ith motif. Conclusion The primary objective of the program is to assess the likelihood that a given DNA segment is CRM regulated with a known set of regulatory factors. In addition, the program can also be used to select the appropriate threshold for PWM scanning. Another application is assessing similarity of different motifs. Availability Project web page, stand-alone version and documentation can be found at http://bioinform.genetika.ru/AhoPro/
- Published
- 2007
- Full Text
- View/download PDF
39. A new approach to admissible alternatives in interval decision making.
- Author
-
Boeva, V. and De Baets, B.
- Published
- 2004
- Full Text
- View/download PDF
40. Decision analysis based on Kripke's semantics.
- Author
-
Boeva, V. and Ekenberg, L.
- Published
- 2002
- Full Text
- View/download PDF
41. Electrokinetic supply of nutrients in soil bioremediation
- Author
-
Boeva, V. and Elektorowicz, M.
- Subjects
SOIL pollution ,ELECTROKINETICS ,POLLUTION - Published
- 1996
42. SEPARATION OF NITROGEN ISOTOPES BY ION EXCHANGE.
- Author
-
Boeva, V
- Published
- 1968
43. Exploring RNA cargo in extracellular vesicles for pleural mesothelioma detection.
- Author
-
Kraft A, Kirschner MB, Orlowski V, Ronner M, Bodmer C, Boeva V, Opitz I, and Meerang M
- Subjects
- Humans, Female, Male, Mesothelioma, Malignant genetics, Mesothelioma, Malignant metabolism, Mesothelioma, Malignant pathology, Mesothelioma, Malignant diagnosis, Transcriptome, Gene Expression Profiling, RNA, Long Noncoding genetics, RNA, Long Noncoding metabolism, Aged, Middle Aged, Extracellular Vesicles metabolism, Extracellular Vesicles genetics, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Pleural Neoplasms genetics, Pleural Neoplasms metabolism, Pleural Neoplasms diagnosis, Pleural Neoplasms pathology, Mesothelioma genetics, Mesothelioma metabolism, Mesothelioma diagnosis, Mesothelioma pathology
- Abstract
Background: Pleural Mesothelioma (PM) is a highly aggressive cancer, for which effective early detection remains a challenge due to limited screening options and low sensitivity of biomarkers discovered so far. While extracellular vesicles (EVs) have emerged as promising candidates for blood-based biomarkers, their role in PM has not been studied yet. In this study, we characterized the transcriptomic profile of EVs secreted by PM primary cells and explored their potential as a biomarker source for PM detection., Methods: We collected cell culture supernatant from early-passage PM cell cultures derived from the pleural effusion of 4 PM patients. EVs were isolated from the supernatant using Qiagen exoEasy Maxi kit. RNA isolation from EVs was done using the mirVana PARIS kit. Finally, single-end RNA sequencing was done with Illumina Novaseq 6000., Results: We identified a range of RNA species expressed in EVs secreted by PM cells, including protein-coding RNA (80%), long non-coding RNA (13%), pseudogenes (4.5%), and short non-coding RNA (1.6%). We detected a subset of genes associated with the previously identified epithelioid (32 genes) and sarcomatoid molecular components (36 genes) in PM-EVs. To investigate whether these markers could serve as biomarkers for PM detection in blood, we compared the RNA content of PM-EVs with the cargo of EVs isolated from the plasma of healthy donors (publicly available data). Majority of upregulated genes in PM-EVs were protein-coding and long non-coding RNAs. Interestingly, 25 of them were the sarcomatoid and epithelioid marker genes. Finally, functional analysis revealed that the PM-EV RNA cargo was associated with Epithelial-Mesenchymal transition, glycolysis, and hypoxia., Conclusions: This is the first study to characterize the transcriptomic profile of EVs secreted by PM primary cell cultures, demonstrating their potential as biomarker source for early detection. Further investigation of the functional role of PM-EVs will provide new insights into disease biology and therapeutic avenues., Competing Interests: Declarations. Code availability: R code used to analyze the data have been provided in the Supplementary Files. Ethics approval and consent to participate: All procedures involving pleural mesothelioma primary cultures were approved by the Ethics Committee of the canton Zurich on 09/02/2021 with the approval number BASEC-Nr. 2020–02566. Consent for publication: Not applicable. Competing interests: IO has received institutional grants from Roche and Medtronic, consulting fees from Intuitive, and lecture honoraria from Roche and AstraZeneca. IO has also participated in advisory boards for AstraZeneca, MSD, BMS and Medtronic. The remaining authors declare no competing interests., (© 2025. The Author(s).)
- Published
- 2025
- Full Text
- View/download PDF
44. sparsesurv: a Python package for fitting sparse survival models via knowledge distillation.
- Author
-
Wissel D, Janakarajan N, Schulte J, Rowson D, Yuan X, and Boeva V
- Subjects
- Proportional Hazards Models, Algorithms, Software, Machine Learning
- Abstract
Motivation: Sparse survival models are statistical models that select a subset of predictor variables while modeling the time until an event occurs, which can subsequently help interpretability and transportability. The subset of important features is often obtained with regularized models, such as the Cox Proportional Hazards model with Lasso regularization, which limit the number of non-zero coefficients. However, such models can be sensitive to the choice of regularization hyperparameter., Results: In this work, we develop a software package and demonstrate how knowledge distillation, a powerful technique in machine learning that aims to transfer knowledge from a complex teacher model to a simpler student model, can be leveraged to learn sparse survival models while mitigating this challenge. For this purpose, we present sparsesurv, a Python package that contains a set of teacher-student model pairs, including the semi-parametric accelerated failure time and the extended hazards models as teachers, which currently do not have Python implementations. It also contains in-house survival function estimators, removing the need for external packages. Sparsesurv is validated against R-based Elastic Net regularized linear Cox proportional hazards models as implemented in the commonly used glmnet package. Our results reveal that knowledge distillation-based approaches achieve competitive discriminative performance relative to glmnet across the regularization path while making the choice of the regularization hyperparameter significantly easier. All of these features, combined with a sklearn-like API, make sparsesurv an easy-to-use Python package that enables survival analysis for high-dimensional datasets through fitting sparse survival models via knowledge distillation., Availability and Implementation: sparsesurv is freely available under a BSD 3 license on GitHub (https://github.com/BoevaLab/sparsesurv) and The Python Package Index (PyPi) (https://pypi.org/project/sparsesurv/)., (© The Author(s) 2024. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF
45. A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples.
- Author
-
Arakawa Y, Elloumi F, Varma S, Khandagale P, Jo U, Kumar S, Roper N, Reinhold WC, Robey RW, Takebe N, Gottesman MM, Thomas CJ, Boeva V, Berruti A, Abate A, Tamburello M, Sigala S, Hantel C, Weigand I, Wierman ME, Kiseljak-Vassiliades K, Del Rivero J, and Pommier Y
- Subjects
- Humans, Animals, Cell Line, Tumor, Mice, Xenograft Model Antitumor Assays, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Databases, Genetic, Precision Medicine methods, Adrenocortical Carcinoma genetics, Adrenocortical Carcinoma drug therapy, Adrenocortical Carcinoma pathology, Adrenal Cortex Neoplasms genetics, Adrenal Cortex Neoplasms drug therapy, Adrenal Cortex Neoplasms pathology, Genomics methods
- Abstract
Adrenocortical carcinoma (ACC) is a rare and highly heterogeneous disease with a notably poor prognosis due to significant challenges in diagnosis and treatment. Emphasizing on the importance of precision medicine, there is an increasing need for comprehensive genomic resources alongside well-developed experimental models to devise personalized therapeutic strategies. We present ACC_CellMinerCDB, a substantive genomic and drug sensitivity database (available at https://discover.nci.nih.gov/acc_cellminercdb) comprising ACC cell lines, patient-derived xenografts, surgical samples, and responses to more than 2,400 drugs examined by the NCI and National Center for Advancing Translational Sciences. This database exposes shared genomic pathways among ACC cell lines and surgical samples, thus authenticating the cell lines as research models. It also allows exploration of pertinent treatment markers such as MDR-1, SOAT1, MGMT, MMR, and SLFN11 and introduces the potential to repurpose agents like temozolomide for ACC therapy. ACC_CellMinerCDB provides the foundation for exploring larger preclinical ACC models., Significance: ACC_CellMinerCDB, a comprehensive database of cell lines, patient-derived xenografts, surgical samples, and drug responses, reveals shared genomic pathways and treatment-relevant markers in ACC. This resource offers insights into potential therapeutic targets and the opportunity to repurpose existing drugs for ACC therapy., (©2024 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
46. Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma.
- Author
-
Yates J, Mathey-Andrews C, Park J, Garza A, Gagné A, Hoffman S, Bi K, Titchen B, Hennessey C, Remland J, Shannon E, Camp S, Balamurali S, Cavale SK, Li Z, Raghawan AK, Kraft A, Boland G, Aguirre AJ, Sethi NS, Boeva V, and Van Allen E
- Abstract
Esophageal adenocarcinoma (EAC) is a highly lethal cancer of the upper gastrointestinal tract with rising incidence in western populations. To decipher EAC disease progression and therapeutic response, we performed multiomic analyses of a cohort of primary and metastatic EAC tumors, incorporating single-nuclei transcriptomic and chromatin accessibility sequencing, along with spatial profiling. We identified tumor microenvironmental features previously described to associate with therapy response. We identified five malignant cell programs, including undifferentiated, intermediate, differentiated, epithelial-to-mesenchymal transition, and cycling programs, which were associated with differential epigenetic plasticity and clinical outcomes, and for which we inferred candidate transcription factor regulons. Furthermore, we revealed diverse spatial localizations of malignant cells expressing their associated transcriptional programs and predicted their significant interactions with microenvironmental cell types. We validated our findings in three external single-cell RNA-seq and three bulk RNA-seq studies. Altogether, our findings advance the understanding of EAC heterogeneity, disease progression, and therapeutic response., Competing Interests: E.M.V.: Advisory/Consulting: Enara Bio, Manifold Bio, Monte Rosa, Novartis Institute for Biomedical Research, Serinus Bio, TracerDx Research support: Novartis, BMS, Sanofi, NextPoint Equity: Tango Therapeutics, Genome Medical, Genomic Life, Enara Bio, Manifold Bio, Microsoft, Monte Rosa, Riva Therapeutics, Serinus Bio, Syapse, TracerDx Travel reimbursement: None Patents: Institutional patents filed on chromatin mutations and immunotherapy response, and methods for clinical interpretation; intermittent legal consulting on patents for Foaley & Hoag Editorial Boards: Science Advances A.J.A. has consulted for Anji Pharmaceuticals, Affini-T Therapeutics, Arrakis Therapeutics, AstraZeneca, Boehringer Ingelheim, Kestrel Therapeutics, Merck & Co., Inc., Mirati Therapeutics, Nimbus Therapeutics, Oncorus, Inc., Plexium, Quanta Therapeutics, Revolution Medicines, Reactive Biosciences, Riva Therapeutics, Servier Pharmaceuticals, Syros Pharmaceuticals, T-knife Therapeutics, Third Rock Ventures, and Ventus Therapeutics. A.J.A. holds equity in Riva Therapeutics and Kestrel Therapeutics. A.J.A. has research funding from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Deerfield, Inc., Eli Lilly, Mirati Therapeutics, Nimbus Therapeutics, Novartis, Novo Ventures, Revolution Medicines, and Syros Pharmaceuticals.
- Published
- 2024
- Full Text
- View/download PDF
47. DNA-methylation variability in normal mucosa: a field cancerization marker in patients with adenomatous polyps.
- Author
-
Yates J, Schaufelberger H, Steinacher R, Schär P, Truninger K, and Boeva V
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Biomarkers, Tumor genetics, Intestinal Mucosa pathology, Intestinal Mucosa metabolism, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Gene Expression Regulation, Neoplastic, Cell Transformation, Neoplastic genetics, CpG Islands genetics, Epigenesis, Genetic, DNA Methylation, Adenomatous Polyps genetics, Adenomatous Polyps pathology
- Abstract
Background: The phenomenon of field cancerization reflects the transition of normal cells into those predisposed to cancer. Assessing the scope and intensity of this process in the colon may support risk prediction and colorectal cancer prevention., Methods: The Swiss Epigenetic Colorectal Cancer Study (SWEPIC) study, encompassing 1111 participants for DNA methylation analysis and a subset of 84 for RNA sequencing, was employed to detect field cancerization in individuals with adenomatous polyps (AP). Methylation variations were evaluated for their discriminative capability, including in external cohorts, genomic localization, clinical correlations, and associated RNA expression patterns., Results: Normal cecal tissue of individuals harboring an AP in the proximal colon manifested dysregulated DNA methylation compared to tissue from healthy individuals at 558 unique loci. Leveraging these adenoma-related differentially variable and methylated CpGs (aDVMCs), our classifier discerned between healthy and AP-adjacent tissues across SWEPIC datasets (cross-validated area under the receiver operating characteristic curve [ROC AUC] = 0.63-0.81), including within age-stratified cohorts. This discriminative capacity was validated in 3 external sets, differentiating healthy from cancer-adjacent tissue (ROC AUC = 0.82-0.88). Notably, aDVMC dysregulation correlated with polyp multiplicity. More than 50% of aDVMCs were significantly associated with age. These aDVMCs were enriched in active regions of the genome (P < .001), and associated genes exhibited altered expression in AP-adjacent tissues., Conclusions: Our findings underscore the early onset of field cancerization in the right colon during the neoplastic transformation process. A more extensive validation of aDVMC dysregulation as a stratification tool could pave the way for enhanced surveillance approaches, especially given its linkage to adenoma emergence., (© The Author(s) 2024. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF
48. DNA hypermethylation driven by DNMT1 and DNMT3A favors tumor immune escape contributing to the aggressiveness of adrenocortical carcinoma.
- Author
-
Kerdivel G, Amrouche F, Calmejane MA, Carallis F, Hamroune J, Hantel C, Bertherat J, Assié G, and Boeva V
- Subjects
- Humans, DNA Methylation, Tumor Escape genetics, Prognosis, DNA, CpG Islands, Phenotype, Adrenocortical Carcinoma genetics, Adrenal Cortex Neoplasms genetics, Colorectal Neoplasms genetics
- Abstract
Background: Adrenocortical carcinoma is rare and aggressive endocrine cancer of the adrenal gland. Within adrenocortical carcinoma, a recently described subtype characterized by a CpG island methylator phenotype (CIMP) has been associated with an especially poor prognosis. However, the drivers of CIMP remain unknown. Furthermore, the functional relation between CIMP and poor clinical outcomes of patients with adrenocortical carcinoma stays elusive., Results: Here, we show that CIMP in adrenocortical carcinoma is linked to the increased expression of DNA methyltransferases DNMT1 and DNMT3A driven by a gain of gene copy number and cell hyperproliferation. Importantly, we demonstrate that CIMP contributes to tumor aggressiveness by favoring tumor immune escape. This effect could be at least partially reversed by treatment with the demethylating agent 5-azacytidine., Conclusions: In sum, our findings suggest that co-treatment with demethylating agents might enhance the efficacy of immunotherapy and could represent a novel therapeutic approach for patients with high CIMP adrenocortical carcinoma., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
49. scROSHI: robust supervised hierarchical identification of single cells.
- Author
-
Prummer M, Bertolini A, Bosshard L, Barkmann F, Yates J, Boeva V, Stekhoven D, and Singer F
- Abstract
Identifying cell types based on expression profiles is a pillar of single cell analysis. Existing machine-learning methods identify predictive features from annotated training data, which are often not available in early-stage studies. This can lead to overfitting and inferior performance when applied to new data. To address these challenges we present scROSHI, which utilizes previously obtained cell type-specific gene lists and does not require training or the existence of annotated data. By respecting the hierarchical nature of cell type relationships and assigning cells consecutively to more specialized identities, excellent prediction performance is achieved. In a benchmark based on publicly available PBMC data sets, scROSHI outperforms competing methods when training data are limited or the diversity between experiments is large., (© The Author(s) 2023. Published by Oxford University Press on behalf of NAR Genomics and Bioinformatics.)
- Published
- 2023
- Full Text
- View/download PDF
50. Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma.
- Author
-
Thirant C, Peltier A, Durand S, Kramdi A, Louis-Brennetot C, Pierre-Eugène C, Gautier M, Costa A, Grelier A, Zaïdi S, Gruel N, Jimenez I, Lapouble E, Pierron G, Sitbon D, Brisse HJ, Gauthier A, Fréneaux P, Grossetête S, Baudrin LG, Raynal V, Baulande S, Bellini A, Bhalshankar J, Carcaboso AM, Geoerger B, Rohrer H, Surdez D, Boeva V, Schleiermacher G, Delattre O, and Janoueix-Lerosey I
- Subjects
- Humans, Cell Line, Tumor, Tumor Microenvironment genetics, Cell Plasticity, Neuroblastoma metabolism
- Abstract
Noradrenergic and mesenchymal identities have been characterized in neuroblastoma cell lines according to their epigenetic landscapes and core regulatory circuitries. However, their relationship and relative contribution in patient tumors remain poorly defined. We now document spontaneous and reversible plasticity between the two identities, associated with epigenetic reprogramming, in several neuroblastoma models. Interestingly, xenografts with cells from each identity eventually harbor a noradrenergic phenotype suggesting that the microenvironment provides a powerful pressure towards this phenotype. Accordingly, such a noradrenergic cell identity is systematically observed in single-cell RNA-seq of 18 tumor biopsies and 15 PDX models. Yet, a subpopulation of these noradrenergic tumor cells presents with mesenchymal features that are shared with plasticity models, indicating that the plasticity described in these models has relevance in neuroblastoma patients. This work therefore emphasizes that intrinsic plasticity properties of neuroblastoma cells are dependent upon external cues of the environment to drive cell identity., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.